Vaderis drug lends hope to patients with bleeding disease HHT

A clinical trial of Vaderis Therapeutics’ AKT inhibitor engasertib suggests it could be the first effective treatment for hereditary haemorrhagic telangiectasia (HHT), the second most common inherited bleeding disorder.

People living with HHT…